Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

36.540
+5.44017.49%
Volume:20.60M
Turnover:748.63M
Market Cap:9.03B
PE:284.39
High:37.840
Open:31.180
Low:31.120
Close:31.100
52wk High:53.450
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:3.43
T/O Rate:15.53%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.128
ROE:0.82%
ROA:-0.80%
PB:1.55
PE(LYR):284.39
PS:6.26

Loading ...

AH Share Premium and Deviation Data for July 20th

Stock News
·
Jul 20

CANSINOBIO Shares Surge on Regulatory Progress for Meningitis Vaccine

Stock News
·
Jul 20

CanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range

Bulletin Express
·
Jul 19

CansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine

Stock News
·
Jul 19

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13

CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement

Bulletin Express
·
Jul 03

AH Share Premium and Deviation Rankings for July 3rd

Stock News
·
Jul 03

CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Argentina

MT Newswires Live
·
Jun 25

CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy

Bulletin Express
·
Jun 25

CansinoBIO Secures Regulatory Approval in Argentina for Meningococcal Vaccine

Stock News
·
Jun 25

CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association

Bulletin Express
·
Jun 10

CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans

Bulletin Express
·
Jun 02

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

MT Newswires Live
·
May 26

CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled

Stock News
·
May 26

CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express
·
May 26

CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates

Bulletin Express
·
May 19

CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates

Bulletin Express
·
May 19

CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China

MT Newswires Live
·
May 11

CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator

Stock News
·
May 11

CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives

Simply Wall St.
·
Apr 30